Objective assessment of inflammation after cataract surgery: Comparison of 3 similar intraocular lens models

Monnet, Dominique; Tepenier, Laure; Brézin, Antoine P.

doi:10.1016/j.jcrs.2008.12.021

Cited by 15 publications

(10 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Phacoemulsification with intraocular lens implantation has become the primary surgery to remove cataracts. However, with the surgery comes the potential for postoperative pain and inflammation, which have long been deemed as acceptable risks given the numerous benefits of cataract surgery 5. The use of nonsteroidal anti-inflammatory drugs (NSAIDs) has been shown to reduce postoperative pain, reduce the risk of postoperative inflammation, and improve patient comfort 6–10.…”

Section: Introductionmentioning

confidence: 99%

Bromfenac ophthalmic solution for the treatment of postoperative ocular pain and inflammation: safety, efficacy, and patient adherence

Rajpal¹,

Ross²,

Rajpal³

et al. 2014

PPA

View full text Add to dashboard Cite

Ophthalmic nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used by clinicians to manage ocular inflammation and pain following cataract surgery. Over the past decade, the US Food and Drug Administration has approved multiple topical NSAIDs for these purposes, including several reformulated products. One of these medications, bromfenac ophthalmic solution, has a long and extensive history, with proven efficacy and safety in patients following cataract surgery. The evolution of bromfenac ophthalmic solution over the years has involved either lowering the concentration of the active ingredient or extending the dosing interval to improve patient adherence/compliance. This review will focus on the history and progression of bromfenac ophthalmic solution and report the available patient preference and adherence data regarding this ocular NSAID throughout its evolution.

show abstract

Section: Introductionmentioning

confidence: 99%

Bromfenac ophthalmic solution for the treatment of postoperative ocular pain and inflammation: safety, efficacy, and patient adherence

Rajpal¹,

Ross²,

Rajpal³

et al. 2014

PPA

View full text Add to dashboard Cite

show abstract

“…With improvements in surgical techniques, patients’ expectations have risen proportionally;3 however, differences in surgical technique impact the severity of surgical trauma and postsurgical recovery 2. The amount of postsurgical ocular pain and inflammation a patient has will play a significant role in his/her perception of the surgical success.…”

Section: Introductionmentioning

confidence: 99%

“…Anterior chamber ocular inflammation, clinically assessed as anterior chamber cell counts and flare, is also common following cataract surgery. However, postoperative inflammation is frequently viewed as an acceptable risk that is largely outweighed by the numerous benefits of cataract surgery 3. The management of postoperative inflammation is essential, both to ensure rapid recovery following the surgery as well as to prevent or decrease the potential for long-term complications, such as cystoid macular edema 5…”

Section: Introductionmentioning

confidence: 99%

The efficacy of bromfenac ophthalmic solution 0.07% dosed once daily in achieving zero-to-trace anterior chamber cell severity following cataract surgery

Silverstein¹,

Jackson²,

Goldberg³

et al. 2014

OPTH

View full text Add to dashboard Cite

PurposeTo evaluate the efficacy of bromfenac ophthalmic solution 0.07% dosed once daily in achieving zero-to-trace (0–5 cells) anterior chamber cells, following cataract surgery with posterior chamber intraocular lens implantation.MethodsThe study designed employed two Phase III, double-masked, placebo-controlled, multicenter clinical trials of 440 subjects, randomized to either bromfenac ophthalmic solution 0.07% (n=222) or placebo (n=218). Subjects self-dosed once daily, beginning 1 day before undergoing cataract surgery with intraocular lens implantation (day –1) and again on the day of surgery (day 0) and for 14 days postoperatively. Follow-up was on days 1, 3, 8, and 15. The outcome measures included the percentage of subjects with zero-to-trace anterior chamber cells at each visit, as determined by the percentage of subjects with ≤5 anterior chamber cells, overall anterior chamber cell grades, and summed ocular inflammation score (SOIS) (combined anterior chamber cell and flare scores).ResultsThe proportion of subjects with zero-to-trace anterior chamber cells was significantly higher in the bromfenac 0.07% group compared with the placebo group as early as day 3 (P=0.0007), continued at day 8 (P<0.0001), and through day 15 (P<0.0001). At day 15, 80.2% of subjects in the bromfenac 0.07% group achieved zero-to-trace anterior chamber cells compared with 47.2% of subjects who did so in the placebo group. The overall anterior chamber cell scores were significantly lower in the bromfenac 0.07% group compared with the placebo group at days 3, 8, and 15 (P<0.0001 at each visit). The SOIS were also significantly lower in the bromfenac group compared with the placebo group at days 3, 8, and 15 (P<0.0001 at each visit).ConclusionBromfenac ophthalmic solution 0.07%, dosed once daily was clinically effective in achieving zero-to-trace anterior chamber cell severity after cataract surgery and was superior to placebo in all anterior chamber cell severity and inflammation outcome measures.

show abstract

“…A comparable performance in the rates of neodymium:YAG (Nd:YAG) capsulotomy between 2 hydrophobic acrylic IOLs made of similar copolymers from a single manufacturer, the SA30AL and the SA60AT (of the same material as the SN60AT model, although without the blue light filter optic) 35 models, has been reported in prospective or retrospective clinical studies. [36][37][38] On the other hand, one should consider that Nd:YAG capsulotomy as a measure of PCO may be an inaccurate estimate of the degree of opacification as it provides a functional measure of significance.…”

Section: Discussionmentioning

confidence: 88%

“…[34][35][36] Both models are made of an aromatic acrylate methacrylate copolymer. The SN60AT model has a biconvex, ultraviolet filtering (blue light filter), 6.0 mm diameter optic and an overall length of 13.0 mm.…”

Section: Methodsmentioning

confidence: 99%

Surface roughness of intraocular lenses with different dioptric powers assessed by atomic force microscopy

Lombardo¹,

Ţălu²,

Ţălu³

et al. 2010

Journal of Cataract and Refractive Surgery

View full text Add to dashboard Cite

show abstract

Objective assessment of inflammation after cataract surgery: Comparison of 3 similar intraocular lens models

Abstract: The 3 IOLs models, including the blue light-filtering model, had similar anterior chamber cells and flare values over a 3-month period, showing the lack of difference in inflammation induced by cataract surgery with implantation of the 3 similar IOL models.

Cited by 15 publications

References 9 publications

Bromfenac ophthalmic solution for the treatment of postoperative ocular pain and inflammation: safety, efficacy, and patient adherence

Bromfenac ophthalmic solution for the treatment of postoperative ocular pain and inflammation: safety, efficacy, and patient adherence

The efficacy of bromfenac ophthalmic solution 0.07% dosed once daily in achieving zero-to-trace anterior chamber cell severity following cataract surgery

Surface roughness of intraocular lenses with different dioptric powers assessed by atomic force microscopy

Contact Info

Product

Resources

About